Infection due to gram-negative bacteria has become an ever increasing problem in recent years (1, 25) . The problem is especially keen in patients with debilitating diseases, patients treated with immunosuppressive agents and corticosteroids, patients receiving antibiotics, and patients with neoplasms treated with chemotherapy (2, 4, 6, 7, 10, 14, 25) .
The antimicrobial agent currently most commonly employed in the treatment of gram-negative infections is the aminoglycoside gentamicin (3, 11, 15, 16) . However, gentamicin is potentially both ototoxic and nephrotoxic, the toxicity being related to the dose administered, the serum level of the drug, and preexisting renal function (12, 23) . Severely ill patients suspected of having an infection, such as febrile patients with underlying leukemia or lymphoma, are often treated with several antibiotics in an attempt to achieve as broad a spectrum of antimicrobial activity as possible (13) . We have begun to examine the susceptibility of gram-negative bacteria to combinations of antimicrobial agents in vitro. We were especially interested in possible synergistic effects of combinations of antimicrobial agents against gram-negative bacteria. Synergy of two antimicrobial agents used in combination might allow lowered doses of each agent to be administered, thus decreas- ing dose-related side effects. In this report we present the results of a study of the effects on susceptibility of gram-negative bacteria of combinations of clindamycin and erythromycin with gentamicin, colimycin, or carbenicillin.
MATERIALS AND METHODS
Eighty-three clinical isolates of gram-negative bacteria were studied. The bacteria were isolated from patient material and identified by the Microbiology Laboratory of The Mt. Sinai Hospital by standard techniques. The isolates included 40 strains of Escherichia coli, 10 of Proteus mirabilis, 10 of Klebsiella sp., nine of Serratia marcescens, eight of Enterobacter aerogenes, and six of Pseudomonas aeruginosa. Minimal inhibitory concentrations (MIC) and minimal bactericidal concentrations of various antimicrobial agents for the clinical isolates were determined by a twofold tube dilution method as previously described (17) . The following antimicrobial agents were tested: clindamycin, colimycin, carbenicillin, erythromycin, gentamicin, cephalothin, ampicillin, tetracycline, and penicillin G.
Six combinations of antimicrobial agents were examined using strains of the six test organisms: clindamycin plus gentamicin; clindamycin plus colimycin; clindamycin plus carbenicillin; erythromycin plus gentamicin; erythromycin plus colimycin; and erythromycin plus carbenicillin. In addition 16 combinations of antibiotics were screened for synergistic activity against five clinical isolates of E. coli. The antibiotic combinations included gentamicin combined with either colimycin, cephalothin, tetracycline, ampicillin, or penicillin G; erythromycin com-bined with either cephalothin, ampicillin, or penicillin G; tetracycline combined with either colimycin, cephalothin, ampicillin, or penicillin G; and ampicillin or penicillin G combined with either clindamycin or colimycin. In these studies, synergy of two antimicrobial agents was defined as inhibition with a fourfold lower concentration of each antibiotic than the individual MIC of the antibiotic (5) . Therefore, to screen for possible synergistic interaction between two antimicrobial agents each antimicrobial agent was added at a concentration one-fourth that of the MIC for the gram-negative organism to be tested.
The kinetics of the bactericidal actions of clindamycin and gentamicin alone and in combination were followed with E. coli 833 serving as the test organism. Two milliliters of a 106 dilution of an overnight growth of the organism were inoculated into four flasks of heart infusion broth (Difco) to prepare a volume of 20 ml of broth containing 60 colony-forming units per ml of the organism. One flask contained various concentrations of clindamycin, a second flask various concentrations of gentamicin, a third flask gentamicin plus clindamycin at the same concentrations of the previous two flasks, and the fourth flask served as a control. The flasks were incubated with shaking at 37 C and 1-ml aliquots were withdrawn at 1, 2, 3, 4, 5, 6, 7, 8, and 24 h for determination of colony counts.
The effects of clindamycin and gentamicin, alone and in combination, on protein synthesis in E. coli 833 also were studied. Two milliliters of a suspension of bacteria (106 colony-forming units/ml) was added to each of four test tubes containing a mixture of 20 "C-labeled L-amino acids (New England Nuclear) at a final concentration of 0.1 MCi/ml. The first tube contained one-fourth the MIC of clindamycin, a second tube one-fourth the MIC of gentamicin, a third clindamycin plus gentamicin at concentrations contained in the previous two tubes, and a fourth tube served as a control. The final volume in each tube was adjusted to 20 ml with heart infusion broth followed by incubation with shaking at 37 C. A zero-time sample and samples at various periods of incubation thereafter were taken by removing 1 ml of each solution into a test tube kept on ice. To each sample was added 0.5 ml (50 mg) of bovine serum albumin (fraction 5, Sigma) followed by 1 ml of cold 10% trichloroacetic acid. The tubes were heated to 90 C for 30 min and then centrifuged at 500 x g for 10 min. The supernatants were discarded and the pellets were washed three times with cold 5% trichloroacetic acid. One-tenth milliliter of 1 N NaOH and 1 ml of NCS (New England Nuclear) were added to each precipitate which was readily solubilized by 15 min of heating at 60 C. The solutions were added to 10 ml of Beckman TLA fluor in toluene and counted in a Beckman LS250 liquid scintillation spectrometer.
The effects of clindamycin and gentamicin, alone and in combination, and clindamycin and colimycin, alone and in combination, on the uptake of clindamycin by E. coli 833 were determined by using tritium-labeled clindamycin. The general experimental procedure was as follows. Each of three tubes contained 14 Ag of tritiated clindamycin (specific activity, 3.61 ACi/mg) per ml; one tube also contained one-fourth the MIC of gentamicin and another tube one-fourth the MIC of colimycin. Each tube contained 2 x 106 colony-forming units of bacteria in the log phase of growth. One-milliliter aliquots were removed from the tubes at zero time and at various periods of incubation thereafter. Bovine serum albumin (50 mg) and 1 ml of cold 10% trichloroacetic acid were added to each tube and the precipitates were washed three times with cold 5% trichloroacetic acid. The pellets were dissolved in NCS and prepared for liquid scintillation spectrometry as described above.
RESULTS
The MICs of the antimicrobial agents were determined for 83 strains of gram-negative bacteria. Most strains (95%) of E. coli were inhibited by <6.25 gg of gentamicin or colimycin per ml whereas 95% of the strains were resistant to clindamycin or erythromycin at concentrations of < 12.5 ,g/ml. Only 50% of strains were inhibited by concentrations of <100 Mg of carbenicillin per ml. Gentamicin and colimycin were bactericidal for 95% of E. coli strains at a concentration of < 12.5 Lg/ml. Colimycin, erythromycin, and clindamycin were inactive against the strains of P. mirabilis tested. These strains were inhibited by carbenicillin and gentamicin at concentrations of <12.5 and <6.25 Ag/ml, respectively. Klebsiella sp. strains (70%) were inhibited by clindamycin at a concentration of < 12.5 ug/ml; erythromycin was inactive against the strains. Many S. marcescens strains (88%) were inhibited by clindamycin at a concentration of < 12.5 Ag/ml; only 11% of the strains were inhibited by clindamycin at this concentration. All strains of E. aerogenes tested were inhibited by concentrations of gentamicin and clindamycin of <6.25 and < 12.5 yg/ml, respectively. All strains of P. aeruginosa were inhibited by <12.5 Mg of gentamicin per ml; 50% of the strains were inhibited by clindamycin at the same concentration.
The combination of clindamycin and gentamicin was synergistic against 24 of 25 E. coli strains tested ( The only other organisms against which the combinations of antimicrobial agents showed significant synergistic effects were isolates of E. aerogenes. The combinations of clindamycin and gentamicin (Table 1 ) and clindamycin and colimycin (Table 1) showed synergistic effects against five and against all eight of the eight strains of E. aerogenes tested, respectively. However, no synergistic effects against E. aerogenes were found with the combination of clindamycin and carbenicillin (Table 1) . Similarly, the combinations of erythromycin and gentamicin and erythromycin and colimycin were synergistic against all eight and seven of the eight E. aerogenes strains tested, respectively. Again, the combination of erythromycin and carbenicillin showed almost no synergistic effect against these organisms. Clindamycin and colimycin were synergistic against 30%, and erythromycin plus colimycin against 50%, of Klebsiella sp. strains tested (Table 1) . Synergistic effects with the combination of erythromycin plus colimycin were found for three of six strains of P. aeruginosa examined. The finding of synergistic effects of the antibiotic combinations for the strains of bacteria tested, except for E. coli and E. aerogenes strains as detailed above, were on the whole quite variable and of low frequency (Table 1) .
Of 16 additional combinations of antibiotics screened for synergistic activity against five clinical isolates of E. coli (Table 2) , only the combination of penicillin G with either gentamicin or colimycin showed synergy against all five isolates. The combination of ampicillin with either gentamicin or colimycin was synergistic against only two and three of the five strains, respectively. Gentamicin combined with either cephalothin or colimycin showed synergy against two of the five strains of E. coli and erythromycin plus cephalothin was synergistic against three of the strains. The other nine antibiotic combinations examined showed either no synergistic effects or synergy against only one of the five strains of E. coli ( Table 2 ). The kinetics of the bactericidal action of subinhibitory but synergistic concentrations of clindamycin and gentamicin against E. coli 833 are shown in Fig. 1 . At a concentration of 0.39 ug of gentamicin per ml (0.25 of the MIC), the growth of E. coli 833 was similar to that of the control. Clindamycin at a concentration of 12.5 ,ug/ml (0.25 of the MIC) initially retarded growth of the bacteria but by 6 h of incubation bacterial growth began to accelerate. By 9 h of incubation the number of viable bacteria present in the incubation mix containing gentamicin plus clindamycin was at least 2 logs less than that in the tubes containing gentamicin or clindamycin alone (Fig. 1) .
The combination of clindamycin and gentamicin inhibited protein synthesis by E. coli 833 to a much greater degree than either antimicrobial agent alone (Fig. 2) . In the experimental conditions used control cultures of E. coli, containing no drug, showed detectable incorporation of radioactive amino acid beginning at 5 h and continuing to increase up to 30 h of incubation (Fig. 2) . Gentamicin at a concentration of 0.39 ,ug/ml (0.25 of the MIC) delayed the onset of detectable protein synthesis and decreased the uptake of amino acid. Incorporation of amino acids increased from 10 to 23 h of incubation and then reached a plateau (Fig. 2) . Clindamycin (12.5 ,g/ml; 0.25 of the MIC) mediated a greater decrease in amino acid uptake than gentamicin. Incorporation of radioactive amino acids began at 10 h and continued through 30 h of incubation (Fig. 2) . No incorporation of labeled amino acid into protein was observed when clindamycin was combined with gentamicin ( Fig. 2) . These data substantiated the marked synergistic effect of clindamycin and gentamicin against growth and division of E. coli.
The effects of gentamicin and colimycin on the uptake of clindamycin by E. coli 833 were investigated using tritiated clindamycin. The uptake of tritiated clindamycin by E. coli 833 was almost instantaneous and maintained a plateau until 2 h of incubation, when clindamycin seemed to be released from the organisms (Fig. 3) . The initial uptake of clindamycin was increased when either gentamicin (+20%) or colimycin (+ 15%) also were present. However, the release phase was much accelerated especially when colimycin was present (Fig. 3) .
DISCUSSION
Synergistic effects of the combination of clindamycin and gentamicin were noted in 96% of isolates of E. coli tested. Fass et al. (5) recently reported on the interaction of clindamycin and gentamicin in vitro and found synergistic effects of the combination against 90% of the 20 strains of E. coli studied. These authors found synergistic effects of the combination of clindamycin and gentamicin against eight of nine strains of P. mirabilis tested, whereas we found such synergistic effects in only three of 10 P. mirabilis strains. We also noted marked synergistic effects against E. coli when clindamycin was combined with colimycin. Erythromycin combined with either gentamicin or colimycin also showed marked synergistic effects against strains of E. coli. In addition, clindamycin or erythromycin combined with carbenicillin was often synergistic against E. coli strains. Thus, clindamycin and erythromycin were found to yield similar results when combined with gentamicin, colimycin, and carbenicillin. Although snyergy of the antibiotics was demonstrated for strains of E. coli and E. aerogenes relatively resistant to ampicillin and carbenicillin, almost no synergy was found for strains of P.
aeruginosa.
Four mechanisms may account for synergistic antimicrobial activity of two drugs (24) former increases; (ii) sequential blocking of two different steps in a metabolic pathway by each drug; (iii) an increase in transport to the site of action of one drug by another; and (iv) the elimination or negation of an inhibitor of one drug by the other drug. Our results do not allow choice of any of these mechanisms. It is noteworthy that no antagonistic effects were noted when either clindamycin or erythromycin were combined with gentamicin. Both lincomycin, the parent compound of clindamycin, and erythromycin bind to the 50S subunit of the ribosome (8) . The binding sites appear to overlap but are different (9) . Erythromycin inhibits translocation whereas lincomycin interferes mainly with the peptidyl transferase reaction (8) . Aminoglycosides such as gentamicin bind to the 30S subunit of the ribosome and cause misreading of messenger ribonucleic acid (8) . Chloramphenicol which also binds to the 50S subunit of the ribosome (8) shows antagonism when combined with gentamicin in vitro (18) and, in certain instances, also in vivo (19) . Chloramphenicol inhibits the peptidyl transferase reaction (8) (20, 21) . In a study of the effects of antibiotic combinations on the generation time of E. coli, Won and Garrett (24) found that erythromycin combined with tetracycline was synergistic but that chloramphenicol or lincomycin combined with tetracycline was indifferent. The data indicated that the three antibiotics attach to overlapping but different binding sites on the ribosome. Indeed there are examples of antagonism between lincomycin and erythromycin in vivo and erythromycin-inducible resistance extends to lincomycin (8) . Clin clindamycin showed antagonistic effects (9). Our results support the strong similarity between clindamycin and erythromycin and indicate a difference in action of the two drugs and chloramphenicol when combined with gentamicin.
Clindamycin and erythromycin also showed synergistic effects when combined with colimycin or carbenicillin. Colimycin affects the cell membrane (8) and carbenicillin, like other penicillins, interferes with cell wall synthesis (8). Carbenicillin was not as active as gentamicin and colimycin in producing synergy. Indeed, the strains of E. coli tested were much less susceptible to carbenicillin than to either gentamicin or colimycin. Interestingly, penicillin G combined with either gentamicin or colimycin was highly synergistic against E. coli.
Our studies with [3H Iclindamycin indicated that the synergistic effects observed with the combinations of clindamycin and gentamicin and clindamycin plus colimycin were not due to a prolonged increase in uptake of clindamycin by the organism. Indeed, the uptake of [3H ]clindamycin seemed to be rather instantaneous and the drug was quickly released as the organisms were killed. At this point we do not know the role in synergy of the initial increase in uptake of clindamycin observed with the antimicrobial combinations.
Generally, combinations of antimicrobial agents are used to provide broad spectrum coverage for infections of mixed etiology, or to produce a greater antibacterial effect against an organism than can be achieved with a single drug. Certainly, the risks of adverse reactions are increased when multiple drugs are administered to a patient. However, against this risk must be weighed the possibility of using lower concentrations of drugs whose toxicity is in great part dose related. The toxicity of aminoglycosides, such as gentamicin, is related to the patient's age, renal function, dose of drug, and peak serum levels (12, 23) . Ideally, when gentamicin is administered serum levels of the drug should be monitored frequently; yet determinations of serum antibiotic levels are not widely available. Thus, in some instances a regimen of an antibiotic combination with a broad spectrum but based on lower than ordinary doses of the drugs may be desirable. Data on the susceptibility of gram-negative bacteria to combinations of clindamycin and erythromycin with gentamicin or colimycin show that synergistic effects can be achieved with a low concentration of either of the latter drugs. When clindamycin was combined with gentamicin 23 of 25 isolates of E. coli were inhibited at gentamicin levels of <0.79 ,g/ml; when clindamycin was combined with colimycin 12 of 16 isolates of E. coli were inhibited by concentrations of colimycin of <0.79 ig/ml. Similar results were obtained when erythromycin was combined with gentamicin or colimycin. Whether these results are applicable to treatment of infections with these antibiotics will require further studies in vivo.
